Connor, Clark & Lunn Investment Management (CC&L)’s Esperion Therapeutics ESPR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-822,618
| Closed | -$1.18M | – | 1550 |
|
|
2025
Q1 | $1.18M | Sell |
822,618
-109,390
| -12% | -$158K | 0.01% | 891 |
|
|
2024
Q4 | $2.05M | Buy |
932,008
+220,730
| +31% | +$486K | 0.01% | 718 |
|
|
2024
Q3 | $1.17M | Buy |
711,278
+295,378
| +71% | +$487K | 0.01% | 831 |
|
|
2024
Q2 | $923K | Buy |
+415,900
| New | +$923K | ﹤0.01% | 867 |
|
|
2024
Q1 | – | Sell |
-352,054
| Closed | -$1.05M | – | 1569 |
|
|
2023
Q4 | $1.05M | Sell |
352,054
-61,650
| -15% | -$184K | ﹤0.01% | 849 |
|
|
2023
Q3 | $405K | Buy |
413,704
+225,767
| +120% | +$221K | ﹤0.01% | 1075 |
|
|
2023
Q2 | $261K | Sell |
187,937
-51,602
| -22% | -$71.7K | ﹤0.01% | 1139 |
|
|
2023
Q1 | $381K | Sell |
239,539
-44,007
| -16% | -$70K | ﹤0.01% | 959 |
|
|
2022
Q4 | $1.77M | Buy |
283,546
+132,042
| +87% | +$823K | 0.01% | 571 |
|
|
2022
Q3 | $1.02M | Buy |
+151,504
| New | +$1.02M | 0.01% | 652 |
|
|
2019
Q4 | – | Sell |
-22,262
| Closed | -$816K | – | 975 |
|
|
2019
Q3 | $816K | Buy |
22,262
+9,125
| +69% | +$334K | 0.01% | 579 |
|
|
2019
Q2 | $611K | Sell |
13,137
-31,088
| -70% | -$1.45M | ﹤0.01% | 681 |
|
|
2019
Q1 | $1.78M | Buy |
44,225
+1,825
| +4% | +$73.3K | 0.01% | 435 |
|
|
2018
Q4 | $1.95M | Buy |
42,400
+950
| +2% | +$43.7K | 0.01% | 423 |
|
|
2018
Q3 | $1.84M | Sell |
41,450
-15,875
| -28% | -$704K | 0.01% | 448 |
|
|
2018
Q2 | $2.25M | Buy |
+57,325
| New | +$2.25M | 0.01% | 450 |
|
|
2015
Q2 | – | Sell |
-6,500
| Closed | -$602K | – | 627 |
|
|
2015
Q1 | $602K | Buy |
+6,500
| New | +$602K | 0.01% | 375 |
|